BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15173127)

  • 1. Is there a rationale for angiotensin blockade in the management of obesity hypertension?
    Sharma AM
    Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases.
    RĂ¼ster C; Wolf G
    Semin Nephrol; 2013 Jan; 33(1):44-53. PubMed ID: 23374893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of arterial hypertension in obese patients.
    Wenzel UO; Benndorf R; Lange S
    Semin Nephrol; 2013 Jan; 33(1):66-74. PubMed ID: 23374895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome.
    Sharma AM; Engeli S
    J Cardiometab Syndr; 2006; 1(1):29-35. PubMed ID: 17675902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension in patients with cardiac hypertrophy].
    Kohno M
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():471-7. PubMed ID: 15171418
    [No Abstract]   [Full Text] [Related]  

  • 10. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adipose tissue renin-angiotensin system in obese].
    Yasue S; Ebihara K; Nakao K
    Nihon Rinsho; 2012 Sep; 70(9):1550-5. PubMed ID: 23012802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory action of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and the prevention of diabetes mellitus in obese patients with hypertension.
    Mascitelli L; Pezzetta F
    Hong Kong Med J; 2005 Oct; 11(5):424. PubMed ID: 16219969
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic considerations in hypertension.
    Tuck ML
    Am J Hypertens; 1990 Dec; 3(12 Pt 2):355S-365S. PubMed ID: 2078323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.